Home » Martin Rosenberg, Mark Bloomfield

Martin Rosenberg, Mark Bloomfield

Feb 16, 2006
Premium

The National Institute of Allergy and Infectious Diseases this week appointed Martin Rosenberg to its principal advisory board.

Rosenberg is chief scientific officer of Promega. He is a director at Promega, Cubist Pharmaceuticals, Medical College of Wisconsin Research Foundation, Nereus Pharmaceuticals, Anacor Pharmaceuticals, and Scarab Genomics.

Applied Biosystems has appointed Mark Bloomfield vice president sales molecular biology Europe as of Nov. 1, 2005, the company announced this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

What You Might Learn

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

From Whales to Urchins to Algae

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

In the Skin

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

This Week in PNAS

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Gene Silencing/Gene Editing

  1. CRISPR Researchers Develop Highly Sensitive Method for Identification of Off-Target Effects In Vivo

  2. Horizon Discovery Revenues Double in H1

  3. Thermo Fisher Licenses CRISPR Patents From Broad Institute, ERS Genomics

  4. Saturation Editing of BRCA1 Exons Reveals Functional, Non-Functional Variants

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.